Semen quality before and after gonadotoxic treatment
Open Access
- 1 March 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 20 (3), 774-781
- https://doi.org/10.1093/humrep/deh671
Abstract
BACKGROUND: The aim of this study was to analyse the semen quality of patients before and after gonadotoxic therapy. PATIENTS AND METHODS: We evaluated semen quality in 314 patients over a 26 year period. The diagnostic categories were leukaemia (n=13); lymphoma (n=128); testicular cancer (n=102); benign conditions (n=13); and other malignant neoplasms (n=58). The degree of azoospermia or oligozoospermia for each disease category was recorded. We then analysed the recovery in semen quality over time for each disease category. RESULTS: The mean patient age was 27.9 years (range 13–65 years). A total of 1115 post-treatment semen samples were analysed from 314 patients. There was a significant reduction in the post-treatment sperm concentration, sperm motility and semen volume compared with pre-treatment levels (P<0.05) in the entire cohort. However, the sperm movement and motility grade remained unaffected. Patients with testicular carcinoma had the lowest pre-treatment sperm concentrations but also the lowest incidence of azoospermia after cancer treatment. Patients with lymphoma and leukaemia had the highest incidence of post-treatment azoospermia and oligospermia. Patients having the largest reductions in their sperm concentration after treatment required the longest recovery period for spermatogenesis. The diagnostic category was the only significant predictor of post-treatment azoospermia. CONCLUSION: Gonadotoxic treatment results in a significant reduction in sperm quality. The type of cancer or disease, and the pre-treatment sperm concentrations were found to be the most significant factors governing post-treatment semen quality and recovery of spermatogenesis. All categories of patients displayed varying degrees of azoospermia and oligozoospermia, and recovery of gonadal function from these states was not significant. This highlights the importance of ensuring sperm banking before treatment, including for patients with benign conditions. Several factors and associations are discussed further in order to give an insight into the pre- and post-gonadotoxic treatment effects.Keywords
This publication has 48 references indexed in Scilit:
- Normal semen parameters in cancer patients presenting for cryopreservation before gonadotoxic therapyFertility and Sterility, 2004
- Decreasing the number of MOPP courses reduces gonadal damage in survivors of childhood hodgkin diseasePediatric Blood & Cancer, 2004
- Prediction of posttreatment spermatogenesis in patients with testicular cancer by flow cytometric sperm chromatin structure assayCytometry, 1997
- Chemotherapy induces transient sex chromosomal and autosomal aneuploidy in human spermNature Genetics, 1997
- Discrepancies in Sperm Count Using Improved Neubauer, Makler, and Horwells Counting ChambersArchives of Andrology, 1993
- Small testicles with impaired production of sperm in adult male survivors of childhood malignanciesCancer, 1990
- Effects of Treatment on Fertility in Long-Term Survivors of Childhood or Adolescent CancerNew England Journal of Medicine, 1987
- Long-term infertility and dominant lethal mutations in male mice treated with adriamycinMutation Research, 1985
- Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVDEuropean Journal of Cancer and Clinical Oncology, 1985
- The effects of Hodgkin's disease and combination chemotherapy on gonadal function in the adult maleCancer, 1982